32
Participants
Start Date
July 3, 2020
Primary Completion Date
November 23, 2021
Study Completion Date
November 23, 2021
CB-280
CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
Placebos
Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
New York Medical College at Westchester Medical Center, Hawthorne
Hershey Medical Center Pennsylvania State University, Hershey
Johns Hopkins University, Baltimore
Virginia Commonwealth University, Richmond
UNC Marsico Clinical Research Center, Chapel Hill
Medical University of South Carolina, Charleston
University of Florida, Gainesville
University Hospitals Cleveland Medical Center, Cleveland
Indiana University, Indianapolis
Billings Clinic, Billings
The Cystic Fibrosis Institute, Glenview
University of Kansas Medical Center, Kansas City
University of Arkansas for Medical Sciences, Little Rock
University of Utah, Salt Lake City
Long Beach Memorial Medical Center, Long Beach
Boston Children's Hospital, Brigham & Women's Hospital, Boston
Vermont Lung Center at the University of Vermont Medical Center, Colchester
University of Calgary, Calgary
St. Pauls' Hospital, Vancouver
McGill University Health Center, Montreal
Lead Sponsor
Calithera Biosciences, Inc
INDUSTRY